Next Phase Newsletter

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston, scheduled for September 25-27, 2024, is Life Science Nation (LSN)‘s upcoming hybrid event that promises to be a pivotal platform for early-stage deal-making in the life sciences sector. The conference will be held at the Westin Copley Place Hotel, with in-person activities on September 25, followed by two days of virtual partnering on September 26-27.

RESI (Redefining Early Stage Investments) is designed to connect start-ups and early-stage investors across the domains of drugs, devices, diagnostics, and digital health. This event is particularly valuable for fundraising executives seeking to establish connections with investors and licensing partners.

One of RESI’s key features is its investor panels, which offer attendees insights into the latest industry trends and provide guidance on how to effectively communicate with potential partners. These panels serve a dual purpose:

• They offer valuable industry insights from experienced investors.

• They provide attendees with opportunities to learn about individual investors and potentially schedule on-site meetings.

The conference caters to companies at various funding stages, from those seeking seed capital ($25K – $2M) to those looking for Series B funding ($10M – $50M). RESI Boston is expected to attract over 300 early-stage life science investors and licensing partners, as well as more than 300 early-stage life science companies.

Check out the panel lineup below and be sure to maximize the benefits of attending RESI Boston, by registering early. Early bird rates, offering a $300 discount, are available until Friday, August 2.

By Caitlin Dolegowski, Marketing Manager, LSN

Life Science Nation (LSN) presents a series of free webinars designed to equip early-stage life science and healthcare entrepreneurs with essential partnering skills. These sessions offer tactical advice and investor insights to maximize outcomes when engaging with potential investors and strategic partners. Participants will learn to craft compelling narratives, develop effective investor targeting strategies, and gain direct insights from active life science investors. The webinars aim to prepare companies for upcoming RESI conferences and other partnering events, providing valuable skills applicable to all fundraising and partnering activities in the sector.

Register for these complimentary webinars to enhance your chances of success in the competitive early-stage life science arena:

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Europe 2024 in Barcelona last week, 41 innovative companies participated in the highly anticipated Innovator’s Pitch Challenge (IPC). This event provided a unique platform for early-stage life science and healthcare companies to showcase their technologies and attract potential investors.

The IPC finalists had the opportunity to deliver 4-minute pitches to an engaged audience, followed by a 9-minute Q&A session with a panel of expert investor judges. Each participating company also exhibited a poster highlighting their technology in the conference’s exhibit hall.

Many of the pitch companies and the winning companies represented the cutting-edge technology emerging from the Catalonia region, with several being member companies of Biocat, RESI Europe’s co-organizer. Biocat plays a crucial role in driving the growth of Catalonia’s life sciences and health innovation ecosystem.

The competition’s unique voting system allowed registered RESI attendees, including startup executives, early-stage investors, and industry experts, to ‘invest’ in their favorite IPC companies using RESI cash provided at check-in. Attendees based their decisions on the companies’ poster presentations and pitch performances.

Life Science Nation is proud to announce the top three winners of RESI Europe 2024’s Innovator’s Pitch Challenge:

1st Place: Gate2Brain

Jaume Baró, Executive Directorate, Enterprise and Entrepeneurship, Barcelona Activa | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Meritxell Teixidó, PhD, CEO & CSO, Gate2Brain | Robert Fabregat, CEO, Biocat

2nd Place: Ysotope Theranostics

3rd Place: DyCare

Jaume Baró, Executive Directorate, Enterprise and Entrepeneurship, Barcelona Activa | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Ricardo Jauregui, CTO & Founder, Dycare | Robert Fabregat, CEO, Biocat

Gate2Brain, the first-place winner, will receive complimentary tickets to three RESI events of their choice, a prize valued at $12,000. The second and third-place winners will receive tickets to two and one RESI events, respectively.

For those interested in participating in the next Innovator’s Pitch Challenge, applications are now open for RESI Boston 2024. This event will take place on September 25 at the Westin Copley Place in Boston, featuring a one-day in-person conference followed by two days of virtual partnering. Early application is encouraged as spots are filled on a rolling basis.

Additionally, registration for RESI Boston is now open with super early bird rates available. Prospective attendees can save $500 by registering before Friday, July 5.

The success of RESI Europe 2024 in Barcelona, with its diverse participation and innovative format, underscores the event’s importance in connecting early-stage life science companies with potential investors and industry partners.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is gearing up for next week’s highly anticipated RESI Europe conference in Barcelona. With a curated program featuring 9 insightful panels, attendees can expect to gain the latest perspectives on early-stage life science and healthcare investment opportunities.

LSN has assembled diverse panelists representing various investment groups, including seed funds, corporate venture capitalists, early-stage therapeutics, and oncology innovation leaders. These experts will share their strategies, approaches to early-stage investment, perspectives on industry landscapes, insights into startup ecosystems, and much more. As a truly global conference, RESI Europe will also welcome numerous international investors and cross-border investment groups, fostering dynamic discussions and facilitating valuable networking opportunities.

The primary goal of the RESI panels is to facilitate constructive conversations between investors and fundraising CEOs. Attendees can expect to receive tactical advice on effective capital-raising strategies and partnership acquisition, empowering companies to navigate the fundraising journey successfully. These must-attend panels present an unparalleled opportunity for founders and CEOs to engage directly with investors, expand their networks, and gain invaluable insights to propel their businesses forward.

Join the panelists below at RESI Europe:

Click Here to See More Investor Speakers

By Momo Yamamoto, Investor Research Analyst, LSN

This week, Life Science Nation (LSN) hosted our June Investor Fireside Chat which brought together four investors from different parts of the world discussing how early-stage life science investments in the first half of 2024 have looked like so far. We were happy to welcome Farzad Abdi-Dezfuli, Partner from Sarsia, Jenna Aronson, Principal from Two Bear Capital, Tom Gibbs, Investment Director from Debiopharm Group, and Rick Jones, Partner from BioAdvance. The investors gave their thoughts on trends of 2024 and insight to startups looking to fundraise.

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Biocat will host a lunch keynote session at RESI Europe 2024 on June 17 at the Hotel Hilton Diagonal Mar in Barcelona. The session, titled “Catalonia’s Advanced Therapies Ecosystem: Shaping the Future of ATMPs in Europe,” will take place in the Ballroom, starting at 12 PM. Leading experts will discuss the pivotal role of Catalonia’s advanced therapies ecosystem in driving innovation and clinical advancements in Advanced Therapy Medicinal Products (ATMPs) across Europe. This session, organized by Biocat, will delve into the region’s innovative landscape, highlighting groundbreaking research, investment opportunities, and cutting-edge developments.

The esteemed panel will be moderated by Robert Fabregat, CEO of BIOCAT, and features prominent figures in the field:

• Fina Lladós, Vice President General Manager Iberia at Amgen
• Silvia Martín-Lluesma, Clinical Senior Manager of Advanced Therapies at Vall d’Hebron Institute of Oncology (VHIO)
• Antoni Matilla, Cofounder and Director of Biointaxis
• Lluís Pareras, Founder and Managing Partner at Invivo Ventures
• Esteve Trias, Executive Medical Director at Leitat Technological Center

Attendees will gain invaluable insights into how Catalonia’s collaborative efforts and strategic initiatives propel Europe to the forefront of advanced therapies. This session is a must-attend for investors, researchers, and industry professionals committed to advancing the field of ATMPs and shaping the future of healthcare. Don’t miss this opportunity to engage with key players and learn about the future of advanced therapies in Europe! If you haven’t registered for RESI Europe yet, you can register now to secure your spot.